Skip to search formSkip to main contentSkip to account menu

ocaratuzumab

Known as: MoAb CD20, monoclonal antibody CD20, monoclonal antibody, CD20 
An Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab specifically binds to CD20… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

AME 133Monoclonal Antibodies
AME-133vLY 2469298antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
An update on newer monoclonal antibodies in lymphoma therapy
Abstract In 2014, an estimated 9.4% of all new cancers in the US were accounted to hematological cancers. Most of these cancers… 
2015
2015
New anti-CD20 monoclonal antibodies: which is the best?
Rituximab (MabTh era â , Rituxan â ), a chimeric immunoglobulin G1 (IgG1) monoclonal antibody (Mab) targeting CD20, has… 
Review
2015
Review
2015
Emerging immunological drugs for chronic lymphocytic leukemia
Introduction: Over the last few years, several new immunological drugs, particularly monoclonal antibodies (mAbs… 
2013
2013
Monoclonal Antibody (mAb)-Based Biotherapy Options for B-lineage Non- Hodgkin's Lymphoma (NHL)
Copyright: © 2013 Uckun FM. This is an open-access article distributed under the terms of the Creative Commons Attribution… 
2012
2012
Efficacy of ocaratuzumab (AME-133v) in relapsed follicular lymphoma patients refractory to prior rituximab.
8081 Background: Ocaratzumab, previously known as AME-133v, is a humanized next-generation anti-CD20 monoclonal antibody. It has… 
2012
2012
Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients with Low-Affinity CD16 Polymorphisms
Abstract 4884 Background: Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab- engineered humanized anti-CD20 monoclonal… 
2012
2012
Pharmacokinetic and Pharmacodynamic Analysis of Ocaratuzumab in 50 Patients with Relapsed Follicular Lymphoma and Low-Affinity FcγRIIIa (CD16a) Polymorphisms.
Abstract 2750 Ocaratuzumab, previously known as AME-133v, is a Fc- and Fab-engineered humanized anti-CD20 monoclonal antibody… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)